Cipla: AGM Notes - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cipla: AGM Notes

Sep 5, 2002

Cipla declared a 30% growth in revenues for the first five months ended August’01 at its AGM held on 4th September'02. Considering 1QFY03 figures, where revenues grew by 35%, the first five months numbers reflect continued better performance in two months viz July & August’02. However, the management gave a conservative revenue guidance of only 20% growth for the year. Exports contribution to shoot
Backed by strong growth in exports, Cipla’s management expects export contribution to rise to 40% in the current year as against 35% for FY02. The new manufacturing facility at Goa has now become operational and the facility is expected to be dedicated for exports. The manufacturing facility has recently secured the WHO (World Health Organisation) and the UK drugs regulator approval to export CFC free asthma inhalers to the international markets.

Anti-asthma exports to Europe to finally begin
The company is set to launch the world’s only budesonide (an asthma drug) formulation in CFC-free, metered-dose inhalers in Germany and throughout Europe. The approval for sale in Germany is expected soon and exports are expected to start by end of the current year. Investors were eyeing this opportunity for a long time, as the market for this product in the west is huge. With CFC (Chlorofluorocarbons) inhalers to be compulsorily phased out by 2010, the eco-friendly non-CFC based inhalers are expected to see a quantum jump in demand going forward. The European market, which is the biggest market for inhaler drugs, is estimated to be around US$ 3.8 bn currently.

Generic strategy
The generic strategy of the company is to enter bulk drug supply arrangements with companies well entranced in the generic markets. These arrangements are typically to supply hard to manufacture specialty bulk drugs. The management also clarified that the company has started selling bulk Omeprazole to the US partner, Andrx (though Andrx selling the drug is still contingent on the ongoing litigation). The company informed that Cipla was looking to market 50-60 products in Europe in the next few years. It has 10 registrations in the US and a further 21 registrations are under discussion. It hopes to file 20-25 APIs (active pharmaceutical ingredient) in the coming year.

New product launches
In the domestic market, Cipla will also be marketing 50-60 new drug formulations in 2002-03 to keep its product portfolio broad-based. The company will shortly launch a new Once a day AIDS dose kit. Currently, the company commands 75% market share for AIDS medication in the Indian market.

Foray in Biotech
The company informed that it is interested in venturing into biotech and Genetic engineering with a suitable foreign partner. Cipla is evaluating options for such possible tie-ups.

No immediate plans for buyback
The shareholders have given an in principal approval for allowing buyback of shares at a later stage. However, the management has denied any immediate intention of a buyback of its shares in the current year.

We maintain our estimates of 23% growth in topline and around 19% growth in bottom line for FY03. At the current market price of Rs 963, the stock trades at around 19x, FY03 E earnings.

Equitymaster requests your view! Post a comment on "Cipla: AGM Notes". Click here!


More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

CIPLA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of CIPLA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 3, 2021 (Close)